Why are Ansell shares on investors' radars today?

Management sees the deal growing sales and earnings.

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ansell Ltd (ASX: ANN) shares are in focus today after the company announced it finalised a major acquisition.

The purchase was made for all of the assets in US-listed entity Kimberly-Clark Corporation (NYSE: KMB)'s personal protective equipment (PPE) business – a deal Ansell initially announced on 8 April 2024.

Despite the completion of this major acquisition, Ansell shares remain steady at $25.90 per share at the time of writing, flat with the previous close of $25.91 apiece. Here's a closer look.

Ansell shares on radar after transaction

Kimberly-Clark is a US consumer goods giant, holding over 175 brands under its banner. Many are household names – Kleenex tissues and Huggies diapers are two examples.

It has a market capitalisation of US$47.8 billion at the time of writing.

The rationale behind the deal was to expand Ansell's product portfolio and market position. The $970 million transaction will see it acquire brands like Kimtech and KleenGuard – both used for anti-contamination against bacteria and viruses.

It also includes several manufacturing assets used in the production of gloves, masks, apparel, and eyewear.

Financial implications

The deal was finalised today after Ansell secured long-term debt financing to settle the balance.

It raised US$377 million via the United States Private Placement (USPP) market. The other portion of the deal was funded through a fully underwritten institutional placement of approximately 17.8 million new Ansell shares on 8 April, where it raised $400 million at $22.45 per share.

Since that date, these investors have made a 15% return on their money as I write.

The new debt facility announced today will replace previous instruments Ansell was using to fund its growth. As such, management noted this should provide Ansell with financial stability going into FY 2025:

The USPP proceeds replace the previously announced fully committed bridge facility which will no longer need to be drawn, with maturities on the notes issued ranging from 5 to 12 years and providing Ansell with long term funding certainty going into FY25.

Outlook for Ansell shares

Despite the size and potential impact of the acquisition, Ansell shares have not seen immediate movement in early trade on Tuesday.

Investors might be taking a wait-and-see approach, considering the complexities and integration efforts associated with such a significant purchase.

But analysts appear to be optimistic about the deal's long-term benefits. According to CommSec, Anshell shares are rated as a moderate buy, with 6 buy and 6 hold recommendations, respectively.

Ansell's management also expects the acquisition to be beneficial. It expects revenues and earnings per share (EPS) to grow directly as a result of the move. We will just have to wait and see if this is positive for Ansell shares or not.

The company's full-year results for FY 2024 are set to be released on 20 August, per the announcement.

In the last 12 months, Ansell shares have slipped over 4.5% into the red. This year to date, the stock has lifted into the green following a 6% return in the past month of trade.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Why are Mesoblast shares jumping 10% to a 52-week high?

This biotech is hitting new highs on Friday. Let's find out why.

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Ansell shares tumble to a 3-month low. Is this a buying opportunity?

Ansell shares have slid to a 3-month low. Could oversold signals point to a buying opportunity for long-term investors?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

These three biotechs show how the sector can produce huge outsized gains, but are they still good value?

These drug developers' shares are trading near 12-month highs.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

This biotech is approaching 20-bagger status within a year and the good news continues to come

This company has just won approval to go ahead with a key clinical trial.

Read more »

An investor sits at a table in front of her laptop with a party hat on her head and a cake next to her symbolising new year's eve but the 4DS Memory share price is plunging so she looks very disappointed and depressed
Healthcare Shares

$5 billion ASX 200 healthcare stock tumbling on CEO exit

Investors are bidding down the ASX 200 healthcare giant on Thursday. Let’s see why.

Read more »

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »